Research about TES genomic effects (at nanomolar concentrations) on asthma symptoms primarily focuses on airway inflammation since this androgen adversely affects type 2 inflammation that is caused by CD4+ Th2 cells (Th2) and group 2 innate lymphoid cells (ILC2s) [58,59]. This evidence concerns the gene CD4 and asthma.